Clinical Trials Logo

Estrogen Receptor Positive Tumor clinical trials

View clinical trials related to Estrogen Receptor Positive Tumor.

Filter by:

NCT ID: NCT05868226 Recruiting - Solid Tumor Clinical Trials

PRE-I-SPY Phase I/Ib Oncology Platform Program

PRE-I-SPY-PI
Start date: December 22, 2022
Phase: Phase 1
Study type: Interventional

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

NCT ID: NCT05333328 Recruiting - Breast Cancer Clinical Trials

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

INTERSTELLAR
Start date: February 6, 2023
Phase: Phase 4
Study type: Interventional

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

NCT ID: NCT04997798 Recruiting - Breast Cancer Clinical Trials

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This is a phase II open-label, multicenter trial assessing the efficacy of combination regimen"Dalpiciclib plus Exemestane plus trastuzumab plus pyrotinib"in early triple positive breast cancer patients.

NCT ID: NCT04602117 Withdrawn - Ovarian Cancer Clinical Trials

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.

NCT ID: NCT04601116 Recruiting - Clinical trials for Breast Cancer Female

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

Start date: January 4, 2021
Phase: Phase 3
Study type: Interventional

Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.

NCT ID: NCT04123262 Recruiting - Clinical trials for Neuroendocrine Tumors

Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

Start date: November 13, 2019
Phase: Phase 2
Study type: Interventional

This is a single-arm, single-stage clinical study of tamoxifen for patients with well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%) HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).

NCT ID: NCT04086875 Active, not recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer

Start date: November 7, 2018
Phase: N/A
Study type: Interventional

This trial studies how well a text-based intervention works in improving adherence to hormone therapy in patients with stage I-III hormone receptor positive breast cancer. Women often require long term therapy with adjuvant hormone therapy to prevent the cancer from returning and to improve overall survival. Side effects from hormone therapy may prevent some women from staying adherent to their medication therapy. A text-based intervention may provide educational information to breast cancer patients who are undergoing adjuvant hormone therapy.

NCT ID: NCT03870399 Completed - Clinical trials for Neuroendocrine Tumors

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

HORMONET
Start date: March 13, 2019
Phase: Phase 2
Study type: Interventional

This is a single-arm, unicentric, single-stage clinical study of tamoxifen for patients with well differentiated neuroendocrine tumors and radiological progression with positive (> 1 percent) HR (estrogen and / or progesterone) expression by IHC. It will evaluate if Tamoxifen exerts antitumor action in patients with well differentiated NET and positive for the expression of HR, estrogen and / or progesterone.

NCT ID: NCT03750396 Recruiting - Breast Cancer Clinical Trials

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

CLEAR
Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.

NCT ID: NCT03644186 Completed - Breast Cancer Clinical Trials

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

TOUCH
Start date: April 16, 2019
Phase: Phase 2
Study type: Interventional

This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade, versus the treatment with paclitaxel in combination with HER2 blockade.